Drug Development news from FierceBiotech
NewsGSK looks to gov. agencies for R&D advice
GlaxoSmithKline's newly appointed CEO Andrew Witty has seen the future of drug development, and government health care systems will play an even bigger role in it. In an interview with the Wall Read more...
Think tank: Industry plays key role in drug dev.
A conservative think tank is riding to the rescue of the drug development industry, insisting that a new study disproves the old argument that drug companies are simply gathering huge windfalls on Read more...
Expert forecasts revolution in drug dev. work
In the not too distant future drug development work will be revolutionized by new computer technology that will "test" experimental therapies on virtual humans, says a new report from Read more...
Deloitte sees 'fundamental shift' in drug dev. strategies
Deloitte sees a major shakeup going on in clinical research strategies at the large pharma companies. Instead of focusing on the development of a small portfolio of Read more...
A new 'religion' at Schering-Plough
Sometimes the most obvious suggestions for improving drug development work are the hardest to anticipate. My initial knee-jerk response to reading the story on Schering-Plough's approach to drug Read more...
R&D spending going gangbusters in China
Everything drug related is going gangbusters in China. Last year, China grabbed $2.2 billion of the Read more...
Beleaguered Viragen liquidates assets
Everyone knows that the biotech drug development process is a gamble. Small developers spend years and tens if not hundreds of millions of dollars trying to bring drugs to market. The lucky ones will Read more...
FDA, Big Pharma team up on drug research center
In all the hoopla over the new FDA funding-and-reform legislation last month, a key provision was Read more...
ALSO NOTED: Galapagos gains development grants;Aastrom to sell stock; and much more...
> Galapagos has garnered €5.2 million in grant money to continue its drug development work. Read more...
| Press ReleasesPRESS RELEASE: Biopharmaceutical infrastructure key to lower drug development costs Biopharmaceutical infrastructure key to lower drug development costs Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the Read more... |
Get more Drug Development coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends